BBCNEWS Verified Live June 4, 2024 16:52:00
But we haven't had that. we've had decades of failed trials in alzheimer's. this is actually the second drug. the first that cleared amyloid, which reported last year, is called lecanemab. works in a very similar way. that is actually licensed in the us at a cost around $27,000 — £21,000. so that gives an idea of what it might cost if it's introduced in the uk. both those drugs could be licensed in the uk next year, but health services here and around the world will have to see if they move now to the era of treatment for alzheimer's. and because there are two drugs, the thought is that per...